Published in Circ J on March 01, 2013
Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab (2009) 2.50
Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am Heart J (2004) 2.09
Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism (2006) 2.01
Left ventricular systolic and diastolic function in normotensive type 1 diabetic patients with or without autonomic neuropathy: a radionuclide ventriculography study. Diabetes Care (2003) 1.79
Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. Curr Med Res Opin (2011) 1.53
The impact of smoking on cardiovascular outcomes and comorbidities in statin-treated patients with coronary artery disease: a post hoc analysis of the GREACE study. Curr Vasc Pharmacol (2013) 1.53
Atorvastatin: safety and tolerability. Expert Opin Drug Saf (2010) 1.47
Acute renal failure due to tumor lysis syndrome in a patient with non-Hodgkin's lymphoma. Ann Hematol (2004) 1.39
Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin (2006) 1.38
Is angioedema a class adverse effect of the angiotensin-converting enzyme inhibitors? Ann Allergy Asthma Immunol (2007) 1.38
CORONA, statins, and heart failure: who lost the crown? Angiology (2008) 1.38
Pheochromocytoma: an update on genetics and management. Endocr Relat Cancer (2007) 1.34
Adrenal incidentaloma: a diagnostic challenge. Hormones (Athens) (2009) 1.29
Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant (2006) 1.24
Prevalence of vascular disease in metabolic syndrome using three proposed definitions. Int J Cardiol (2006) 1.12
IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis. Arch Med Sci (2011) 1.12
Hyperuricemia as a risk factor for cardiovascular disease. Expert Rev Cardiovasc Ther (2014) 1.11
Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients. Am J Cardiol (2007) 1.09
Pleiotropic effects of statins--clinical evidence. Curr Pharm Des (2009) 1.08
Cold temperature and cardiovascular mortality. Circ J (2013) 1.07
Comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property". Dig Liver Dis (2012) 1.06
Metabolic syndrome in clinical practice. Cardiol J (2014) 1.06
Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study. Arch Med Sci (2013) 1.01
Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population. Curr Med Res Opin (2010) 1.01
Should adipokines be considered in the choice of the treatment of obesity-related health problems? Curr Drug Targets (2010) 1.01
Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opin Pharmacother (2008) 1.00
Dyslipidemia as a risk factor for ischemic stroke. Curr Top Med Chem (2009) 0.99
Dyslipidaemia, hypercoagulability and the metabolic syndrome. Curr Vasc Pharmacol (2006) 0.99
Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. Arch Med Sci (2011) 0.96
Vitamin D and cardiovascular disease: a novel agent for reducing cardiovascular risk? Curr Vasc Pharmacol (2010) 0.95
Non-alcoholic fatty liver disease in type 2 diabetes: pathogenesis and treatment options. Curr Vasc Pharmacol (2012) 0.95
Triglycerides and vascular risk: insights from epidemiological data and interventional studies. Curr Drug Targets (2009) 0.95
Statin discontinuation: an underestimated risk? Curr Med Res Opin (2008) 0.95
Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis. Angiology (2011) 0.94
Acupuncture in the treatment of obesity: a narrative review of the literature. Acupunct Med (2012) 0.94
Is there an additional benefit from coronary revascularization in diabetic patients with acute coronary syndromes or stable angina who are already on optimal medical treatment? Arch Med Sci (2011) 0.94
Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association? Curr Opin Cardiol (2010) 0.94
Do we need to consider inflammatory markers when we treat atherosclerotic disease? Atherosclerosis (2008) 0.94
Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk? Curr Vasc Pharmacol (2011) 0.94
Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches. Nutrients (2013) 0.94
Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution? Expert Opin Pharmacother (2007) 0.93
Hyperuricaemia: more than just a cause of gout? J Cardiovasc Med (Hagerstown) (2013) 0.92
Lipoprotein a: where are we now? Curr Opin Cardiol (2009) 0.92
Eplerenone relieves spironolactone-induced painful gynaecomastia in a patient with primary aldosteronism. Nephrol Dial Transplant (2006) 0.92
Carbon dioxide balneotherapy and cardiovascular disease. Int J Biometeorol (2010) 0.92
Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia? Expert Opin Pharmacother (2007) 0.91
Are we getting to lipid targets in real life? Arch Med Sci (2010) 0.90
Lipid-lowering agents and new onset diabetes mellitus. Expert Opin Pharmacother (2010) 0.90
Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment. Open Cardiovasc Med J (2011) 0.90
11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders? Metabolism (2012) 0.89
Statins exert multiple beneficial effects on patients undergoing percutaneous revascularization procedures. Curr Drug Targets (2007) 0.89
Rectus sheath hematoma: a simplified emergency surgical approach. Open Cardiovasc Med J (2011) 0.88
The role of endocannabinoid system blockade in the treatment of the metabolic syndrome. J Clin Pharmacol (2007) 0.88
Atherogenesis in renal patients: a model of vascular disease? Curr Vasc Pharmacol (2008) 0.87
Targeting vascular risk in patients with metabolic syndrome but without diabetes. Metabolism (2005) 0.87
Effect of tobacco smoking and smoking cessation on plasma lipoproteins and associated major cardiovascular risk factors: a narrative review. Curr Med Res Opin (2013) 0.87
Effect of pioglitazone on heart function and N-terminal pro-brain natriuretic peptide levels of patients with type 2 diabetes. Acta Diabetol (2007) 0.86
Anti-inflammatory effects of fibrates: an overview. Curr Med Chem (2009) 0.86
Plasma visfatin and retinol binding protein-4 levels in patients with type 2 diabetes mellitus and their relationship to adiposity and fatty liver. Clin Biochem (2011) 0.86
Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone? Ann Med (2011) 0.86
Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy. Expert Opin Pharmacother (2010) 0.85
Has the time come for a new definition of microalbuminuria? Curr Vasc Pharmacol (2008) 0.85
Effect of quinapril or losartan alone and in combination on left ventricular systolic and diastolic functions in asymptomatic patients with diabetic autonomic neuropathy. J Diabetes Complications (2006) 0.85
Implementation of guidelines for the management of arterial hypertension. The impulsion study. Open Cardiovasc Med J (2009) 0.85
Are statins 'IDEAL' for non-alcoholic fatty liver disease? Curr Med Res Opin (2013) 0.84
Total serum insulin-like growth factor-1 and C-reactive protein in metabolic syndrome with or without diabetes. Angiology (2006) 0.84
Statins and the risk of diabetes: the debate. Arch Intern Med (2012) 0.84
The role of statins for the primary and secondary prevention of coronary heart disease in women. Curr Pharm Des (2009) 0.84
Editorial: should chronic kidney disease be considered as a coronary heart disease equivalent? Curr Vasc Pharmacol (2012) 0.84
Effects of statin treatment on endothelial function, oxidative stress and inflammation in patients with arterial hypertension and normal cholesterol levels. J Hypertens (2011) 0.84